Guangzhou FineImmune Biotechnology Co., LTD. Report issue

Government Phase 1

Organization Overview

First Clinical Trial
2019
NCT03891706
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Guangzhou FineImmune Biotechnology Co., LTD.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 4